S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30

PMV Pharmaceuticals Stock Forecast, Price & News

+0.56 (+3.33%)
(As of 01/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
555,700 shs
Average Volume
787,240 shs
Market Capitalization
$787.80 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PMVP News and Ratings via Email

Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PMV Pharmaceuticals logo

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function. It is also developing p53 R273H mutation and other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$8.02 per share


Net Income
$-34.44 million
Pretax Margin




Free Float
Market Cap
$787.80 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.36 out of 5 stars

Medical Sector

230th out of 1,415 stocks

Pharmaceutical Preparations Industry

98th out of 683 stocks

Analyst Opinion: 3.4Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -

PMV Pharmaceuticals (NASDAQ:PMVP) Frequently Asked Questions

Is PMV Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PMV Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PMV Pharmaceuticals stock.
View analyst ratings for PMV Pharmaceuticals
or view top-rated stocks.

Are investors shorting PMV Pharmaceuticals?

PMV Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 3,700,000 shares, an increase of 18.2% from the December 15th total of 3,130,000 shares. Based on an average trading volume of 430,500 shares, the days-to-cover ratio is presently 8.6 days. Currently, 13.4% of the shares of the stock are short sold.
View PMV Pharmaceuticals' Short Interest

When is PMV Pharmaceuticals' next earnings date?

PMV Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 2nd 2022.
View our earnings forecast for PMV Pharmaceuticals

How were PMV Pharmaceuticals' earnings last quarter?

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) issued its quarterly earnings data on Friday, November, 12th. The company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.03.
View PMV Pharmaceuticals' earnings history

What price target have analysts set for PMVP?

4 Wall Street analysts have issued 12 month price objectives for PMV Pharmaceuticals' shares. Their forecasts range from $43.00 to $62.00. On average, they expect PMV Pharmaceuticals' stock price to reach $53.67 in the next twelve months. This suggests a possible upside of 209.1% from the stock's current price.
View analysts' price targets for PMV Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are PMV Pharmaceuticals' key executives?

PMV Pharmaceuticals' management team includes the following people:
  • Dr. David H. Mack, Co-Founder, CEO, Pres & Director (Age 59, Pay $770.33k)
  • Dr. Arnold J. Levine Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board (Age 81, Pay $110k)
  • Mr. Winston Kung, COO & CFO (Age 45, Pay $608.93k) (LinkedIn Profile)
  • Dr. Leila Alland, Chief Medical Officer (Age 58, Pay $629.67k) (LinkedIn Profile)
  • Dr. Thomas E. Shenk Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 74)
  • Mr. Robert Ticktin, Gen. Counsel & Company Sec. (Age 59)
  • Dr. Deepika Jalota Pharm.D., Chief Regulatory & Quality Assurance Officer (Age 44)

What other stocks do shareholders of PMV Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PMV Pharmaceuticals investors own include Vical (VICL), Arista Networks (ANET), Apollo Medical (AMEH), Advanced Micro Devices (AMD), Ambarella (AMBA), Alexion Pharmaceuticals (ALXN), Akoustis Technologies (AKTS), Agios Pharmaceuticals (AGIO), Admiral Group (ADM) and Adobe (ADBE).

When did PMV Pharmaceuticals IPO?

(PMVP) raised $126 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is PMV Pharmaceuticals' stock symbol?

PMV Pharmaceuticals trades on the NASDAQ under the ticker symbol "PMVP."

Who are PMV Pharmaceuticals' major shareholders?

PMV Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Asymmetry Capital Management L.P. (0.22%). Company insiders that own PMV Pharmaceuticals stock include Arnold J Levine, Arnold J Levine, David Henry Mack, Euclidean Capital Llc, Laszlo Kopits, Leila Alland, Ling Zang, Paul Klauder, Ra Capital Management, LP, Richard A Heyman, Thilo Schroeder and Winston Kung.
View institutional ownership trends for PMV Pharmaceuticals

Which institutional investors are selling PMV Pharmaceuticals stock?

PMVP stock was sold by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P.. Company insiders that have sold PMV Pharmaceuticals company stock in the last year include Arnold J Levine, David Henry Mack, Euclidean Capital Llc, Laszlo Kopits, Leila Alland, Ling Zang, Paul Klauder, Richard A Heyman, Thilo Schroeder, and Winston Kung.
View insider buying and selling activity for PMV Pharmaceuticals
or view top insider-selling stocks.

How do I buy shares of PMV Pharmaceuticals?

Shares of PMVP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PMV Pharmaceuticals' stock price today?

One share of PMVP stock can currently be purchased for approximately $17.36.

How much money does PMV Pharmaceuticals make?

PMV Pharmaceuticals has a market capitalization of $787.80 million. The company earns $-34.44 million in net income (profit) each year or $2.65 on an earnings per share basis.

How many employees does PMV Pharmaceuticals have?

PMV Pharmaceuticals employs 44 workers across the globe.

What is PMV Pharmaceuticals' official website?

The official website for PMV Pharmaceuticals is www.pmvpharma.com.

How can I contact PMV Pharmaceuticals?

The company can be reached via phone at 609-642-6670 or via email at [email protected].

This page was last updated on 1/25/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.